TempraMed Technologies Ltd., a leading innovator of advanced temperature-controlled medical devices, is honoured to announce its definitive exclusive distribution partnership with Dolfin Sağlık Ürünleri. The intention of TempraMed to join hands with this Turkish company is to distribute its excellence and promote its performance in the market by selling its TempraMed’s “VIVI” line of treatment temperature-balancing products across the Turkish healthcare market.
Dolfin Sağlık Ürünleri entered the healthcare market in 2002 and became Turkey’s most popular and trustworthy medical supplies and device company. This firm delivers an infinite number of healthcare stakeholders, such as public and private hospitals, educational institutions, emergency/ambulance services, and provincial health directorates. The company has earned this national recognition, strongly rooted in customer service, technological innovation and reliability, while offering robust premium medical solutions throughout the country.
Since Turkey has the highest number of individuals with diabetes in Europe because of urbanisation, low screening compliance, obesity rates and diet. The Turkish diabetes sector paves the way for new commercialisation opportunities for TempraMed and many other companies seeking to enter the Turkey healthcare market. TempraMed’s VIVI products will eliminate the need for safeguarding critical medications, conventional cooling such as Epi Pens, fertility medications, biologics, insulin and GLP-1 therapies.
This will bring a major shift in temperature-based treatment by switching from impulsively extreme to patented intelligent insulation technology. This agreement bolsters TempraMed’s universal commercialisation strategy to transform its online direct-to-consumer channels to retail pharmacy networks, insurers, institutional healthcare partners, and regional distributors. This collaboration with Dolfin Sağlık Ürünleri might leverage the market penetration within the GLP-1 and insulin-dependent population with the help of providers and patients, involving diabetes educators, national purchasing entities, family medicine clinics and hospitals.
The CEO of TempraMed, Ron Nagar, said, “Dolfin has been one of the best Turkey’s leading medical distributors with 20 20-years of excellent experience in clinical product procurement, delivery and service and its intense and valuable professional relationships throughout the hospitals, individual patient networks, educational institutions and emergency care make them a powerful and perfect commercialisation partner.”
“This partnership leverages our extension into a fast-growing and huge sector that will support insulin users throughout Turkey with the promise of safety to protect their medication in real-world situations.” Ron also claimed that this deal stands as a major driver of the strategic expansion plan.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
